<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548311</url>
  </required_header>
  <id_info>
    <org_study_id>763</org_study_id>
    <nct_id>NCT03548311</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Ultra-high Dose Methylcobalamin for ALS</brief_title>
  <acronym>JETALS</acronym>
  <official_title>Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tokushima</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tokushima</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week)
      methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis
      (ALS) patients, we enroll ALS patients diagnosed by revised-Awaji-El Escorial criteria within
      12 months after the clinical onset. First they are followed for 12 weeks with Amyotrophic
      Lateral Sclerosis Functional Rating Scale-Revised(ALSFRS-R) scores, and only those who
      exhibit drops of 1-2 points are allowed to enter into the test period. A total of 128
      patients are randomized and the half having placebo. They are blindly evaluated for drops of
      ALSFRS-R in 16 weeks, as the primary outcome. After this, all subjects receive
      methylcobalamin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blinded randomized controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>during 16 weks of test period</time_frame>
    <description>Drop of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>time period from drug assignment to death or becoming bound to respirator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Functional Vital Capacity (FVC)</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>changes of per cent Functional Vital Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homocystein</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>changes of serum levels of homocystein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing (MMT)</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>changes of sum of Medical Research Council scales of manual muscle testing, ranging 5 (normal), 4, 4+, 3, 2, 1, 0 (minimal) ( for analysis each is converted to 6, 5, 4, 3, 2, 1, 0) of the 11 muscles in the limbs (5x2) and neck(1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norris scale</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>changes of Norris scale (39 normal - 0 worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Power</measure>
    <time_frame>during 16 weeks of test period</time_frame>
    <description>changes of sum of grip power in kilograms on both sides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)</measure>
    <time_frame>during 16 weks of test period</time_frame>
    <description>changes of sum of ALSAQ-40 (40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire) score (40 normal - 200 worst)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>safety</measure>
    <time_frame>during 16 weks of test period</time_frame>
    <description>any adverse events during the study period</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramuscular injection of saline solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylcobalamin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection of methylcobalamin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylcobalamin</intervention_name>
    <description>Patients receive methylcobalamin 50mg intramuscular injection twice a week.</description>
    <arm_group_label>methylcobalamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>Patients receive saline solution intramuscular injection twice a week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALS patients within 12 months after clinical onset at the entry

          -  Updated Awaji combined with El Escorial criteria: definite, probably or laboratory
             supported probable

          -  Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks

          -  Japanese Clinical Severity Scale 1 or 2

          -  Those who can visit the participating medical centers

        Exclusion Criteria:

          -  Those who have tracheostomy

          -  Those who had NIPPV

          -  %FVC&lt;60%

          -  Those who have Chronic Obstructive Pulmonary Disease (COPD)

          -  Those who have symptoms and signs of B12 deficiency

          -  Those who had edaravone less than 4 weeks prior to entry

          -  Those who changed the schedule and dosing of riluzole

          -  Those who have dementia

          -  Those who have the possibility of pregnancy

          -  Those who have serious respiratory or cardiac diseases

          -  Those who have malignancies

          -  Those who participated other clinical trials within 12 weeks

          -  Those who have allergies to B12 and related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryuji Kaji, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tokushima University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuisin Izumi, MD</last_name>
    <phone>81-88-633-7207</phone>
    <email>yizumi@tokushima-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryosuke Oki, MD</last_name>
    <phone>81-88-633-9658</phone>
    <email>oki.ryosuke@tokushima-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoki Atsuta, MD</last_name>
      <phone>81-52-741-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyoshi Neurological Clinic</name>
      <address>
        <city>Miyoshi</city>
        <state>Hiroshima</state>
        <zip>728-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaya Oda, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Shimohama, MD</last_name>
      <phone>81-11-611-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe Central Munincipal Medical center</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuo Kohara, MD</last_name>
      <phone>81-78-302-4321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ioh National Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyonobu Komai, MD</last_name>
      <phone>81-76-258-1180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitasato University East Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0380</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makiko Nagai, MD</last_name>
      <phone>81-42-748-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga Medical University Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makoto Urushidani, MD</last_name>
      <phone>81-77-548-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Kuwabara, MD</last_name>
      <phone>81-43-222-7171</phone>
      <email>kuwabara-s@faculty.chiba-u.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Murakami Karindo Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Kikuchi, MD</last_name>
      <phone>81-92-811-3331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>770-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Abe, MD</last_name>
      <phone>88-86-223-7151</phone>
      <email>abekabek@cc.okayama-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Nodera, MD</last_name>
      <phone>81-88-633-9658</phone>
      <email>hnodera@tokushima-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuaki Kanai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toho University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Sonoo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Neurological Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>183-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidefumi Ito, MD</last_name>
      <phone>81-73-447-2300</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015 Jul 15;354(1-2):70-4. doi: 10.1016/j.jns.2015.04.052. Epub 2015 May 8.</citation>
    <PMID>25982504</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaji R, Kodama M, Imamura A, Hashida T, Kohara N, Ishizu M, Inui K, Kimura J. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998 Dec;21(12):1775-8.</citation>
    <PMID>9843082</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tokushima</investigator_affiliation>
    <investigator_full_name>Ryuji Kaji</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>anonymous data are available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>from October 1, 2017 till March 31, 2020</ipd_time_frame>
    <ipd_access_criteria>those who have approval from Institutional Review Board (IRB)</ipd_access_criteria>
    <ipd_url>http://als-mecobalamin.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

